title: Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study.
abstract: OBJECTIVE
  To compare the effect of wavefront-guided and wavefront-optimized LASIK using different laser platforms on subjective quality of vision.
  
  
  METHODS
  The dominant eyes of 55 participants with myopia were randomized to receive either wavefront-guided LASIK treatment by the VISX Star S4 IR Custom-Vue excimer laser system (Abbott Medical Optics, Inc., Santa Clara, CA) or wavefront-optimized treatment by the WaveLight Allegretto Wave Eye-Q 400-Hz excimer laser system (Alcon Laboratories, Inc., Fort Worth, TX), whereas the fellow eye had the alternate laser treatment. Patients completed a questionnaire assessing quality of vision and visual symptoms (daytime and nighttime glare, daytime and nighttime clarity, halos, haze, fluctuating vision, and double vision) preoperatively and at postoperative months 1, 3, 6, and 12.
  
  
  RESULTS
  At 3, 6, and 12 months postoperatively, there was no significant difference in any individual symptom between the wavefront-guided and wavefront-optimized groups, although at 12 months wavefront-guided eyes trended toward having more excellent vision (wavefront-guided vs wavefront-optimized; 2.26 vs 2.43; P = .039). In the subgroup of patients with preoperative root mean square (RMS) higher order aberrations (HOAs) less than 0.3 µm in both eyes, the wavefront-optimized group demonstrated a trend toward worsened nighttime clarity (P = .009), daytime clarity (P = .015), and fluctuating vision (P = .046), and less excellent vision (P = .009) at 12 months.
  
  
  CONCLUSIONS
  Twelve months after surgery, most patients' self-reported visual symptoms were similar in eyes receiving wavefront-guided or wavefront-optimized LASIK. In general, 36% of patients preferred wavefront-guided LASIK, 19% preferred wavefront-optimized LASIK, and 45% had no preference at 12 months. The wavefront-guided preference was more pronounced in patients with lower baseline HOAs (RMS < 0.3 µm).
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Kung
authors.forename: Edward E
authors.initials: EE
authors.lastname: Manche
mesh_terms: D000328:Adult; D003319:Corneal Stroma / Q000503:physiopathology / Q000601:surgery*; D023882:Dominance, Ocular; D005260:Female; D006801:Humans; D020731:Keratomileusis, Laser In Situ / Q000379:methods*; D054018:Lasers, Excimer / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000503:physiopathology / Q000601:surgery*; D017060:Patient Satisfaction; D011446:Prospective Studies; D011785:Quality Assurance, Health Care; D013524:Surgical Flaps; D011795:Surveys and Questionnaires; D014786:Vision Disorders / Q000503:physiopathology; D014785:Vision, Ocular / Q000502:physiology*; D014792:Visual Acuity / Q000502:physiology*; D055815:Young Adult